Key Takeaways
- J&J’s immunology blockbuster Stelara, Amgen’s bone health drug Prolia/Xgeva and Novartis’s heart failure medicine Entresto are among drugs facing loss of exclusivity in 2025.
- Prolia and Entresto are both the top-selling drugs for their respective manufacturers, but Amgen and Novartis are still forecasting overall growth this year.
- The year marks the start of a challenging period for pharmaceutical manufactures in which many blockbuster drugs will face LOEs.
The big patent cliff drug developers and investors have been worrying about has arrived – the period of time running from 2025-2030, when dozens of major blockbuster drugs are expected to face generic or biosimilar competition for the first time
Among the drugs losing US patent protection this year are Johnson & Johnson’s immunology blockbuster Stelara (ustekinumab), Amgen’s bone health drug Prolia/Xgeva (denosumab), Novartis’s heart failure medicine Entresto (sacubitril/valsartan) and AstraZeneca’s